These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 28205231)

  • 41. Pancreatic cancer: Are "liquid biopsies" ready for prime-time?
    Lewis AR; Valle JW; McNamara MG
    World J Gastroenterol; 2016 Aug; 22(32):7175-85. PubMed ID: 27621566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
    Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
    Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
    Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
    Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.
    Evrard C; Ingrand P; Rochelle T; Martel M; Tachon G; Flores N; Randrian V; Ferru A; Haineaux PA; Goujon JM; Karayan-Tapon L; Tougeron D
    Dig Liver Dis; 2023 Nov; 55(11):1562-1572. PubMed ID: 37308396
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
    Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R
    Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer.
    Hsu HC; Lapke N; Wang CW; Lin PY; You JF; Yeh CY; Tsai WS; Hung HY; Chiang SF; Chen HC; Chen SJ; Hsu A; Yang TS
    Mol Cancer Ther; 2018 Oct; 17(10):2238-2247. PubMed ID: 29997152
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
    Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
    Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.
    Parikh AR; Mojtahed A; Schneider JL; Kanter K; Van Seventer EE; Fetter IJ; Thabet A; Fish MG; Teshome B; Fosbenner K; Nadres B; Shahzade HA; Allen JN; Blaszkowsky LS; Ryan DP; Giantonio B; Goyal L; Nipp RD; Roeland E; Weekes CD; Wo JY; Zhu AX; Dias-Santagata D; Iafrate AJ; Lennerz JK; Hong TS; Siravegna G; Horick N; Clark JW; Corcoran RB
    Clin Cancer Res; 2020 Apr; 26(8):1877-1885. PubMed ID: 31941831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The dynamic range of circulating tumor DNA in metastatic breast cancer.
    Heidary M; Auer M; Ulz P; Heitzer E; Petru E; Gasch C; Riethdorf S; Mauermann O; Lafer I; Pristauz G; Lax S; Pantel K; Geigl JB; Speicher MR
    Breast Cancer Res; 2014 Aug; 16(4):421. PubMed ID: 25107527
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
    Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
    BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer.
    Zhou J; Chang L; Guan Y; Yang L; Xia X; Cui L; Yi X; Lin G
    PLoS One; 2016; 11(7):e0159708. PubMed ID: 27459628
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
    Brychta N; Krahn T; von Ahsen O
    Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
    van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
    BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma.
    Bidard FC; Madic J; Mariani P; Piperno-Neumann S; Rampanou A; Servois V; Cassoux N; Desjardins L; Milder M; Vaucher I; Pierga JY; Lebofsky R; Stern MH; Lantz O
    Int J Cancer; 2014 Mar; 134(5):1207-13. PubMed ID: 23934701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer.
    Beránek M; Sirák I; Vošmik M; Petera J; Drastíková M; Palička V
    Acta Medica (Hradec Kralove); 2016; 59(2):54-8. PubMed ID: 27526306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma.
    Cai ZX; Chen G; Zeng YY; Dong XQ; Lin MJ; Huang XH; Zhang D; Liu XL; Liu JF
    Int J Cancer; 2017 Sep; 141(5):977-985. PubMed ID: 28543104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.
    Olsson E; Winter C; George A; Chen Y; Howlin J; Tang MH; Dahlgren M; Schulz R; Grabau D; van Westen D; Fernö M; Ingvar C; Rose C; Bendahl PO; Rydén L; Borg Å; Gruvberger-Saal SK; Jernström H; Saal LH
    EMBO Mol Med; 2015 Aug; 7(8):1034-47. PubMed ID: 25987569
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review.
    Parimi S; Ko JJ
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):939-949. PubMed ID: 28737470
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
    Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
    J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma.
    Luo H; Li H; Hu Z; Wu H; Liu C; Li Y; Zhang X; Lin P; Hou Q; Ding G; Wang Y; Li S; Wei D; Qiu F; Li Y; Wu S
    Biochem Biophys Res Commun; 2016 Mar; 471(4):596-602. PubMed ID: 26876573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.